Abstract
Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer’s disease (AD). The use of fully automated biomarker assays has been shown to reduce the intra- and inter-laboratory variability, which is a critical factor when defining cut-off values. The calculation of cut-off values is often influenced by the composition of AD and control groups. Indeed, the clinically defined AD group may include patients affected by other forms of dementia, while the control group is often very heterogeneous due to the inclusion of subjects diagnosed with other neurological diseases (OND). In this context, unsupervised machine learning approaches may overcome these issues providing unbiased cut-off values and data-driven patient stratification according to the sole distribution of biomarkers. In this work, we took advantage of the reproducibility of automated determination of the CSF core AD biomarkers to compare two large cohorts of patients diagnosed with different neurological disorders and enrolled in two centers with established expertise in AD biomarkers. We applied an unsupervised Gaussian mixture model clustering algorithm and found that our large series of patients could be classified in six clusters according to their CSF biomarker profile, some presenting a typical AD-like profile and some a non-AD profile. By considering the frequencies of clinically defined OND and AD subjects in clusters, we subsequently computed cluster-based cut-off values for Aβ42/Aβ40, p-tau, and t-tau. This approach promises to be useful for large-scale biomarker studies aimed at providing efficient biochemical phenotyping of neurological diseases.
Highlights
Alzheimer’s disease (AD) is the most common neurodegenerative disorder evolving to dementia (Goedert and Spillantini, 2006)
We used the reproducibility of automated Cerebrospinal fluid (CSF) core AD biomarker determination to compare two large cohorts of patients diagnosed with various neurological disorders and enrolled in two centers with proven expertise in AD biomarkers
In order to overcome the diagnostic heterogeneity of both AD and control groups, we applied unsupervised Gaussian mixture model (GMM) to cluster the patients (n = 616) according to their CSF biomarker profile and investigate the degree of overlap between the clinical diagnosis and the data-driven classification of the subjects
Summary
Alzheimer’s disease (AD) is the most common neurodegenerative disorder evolving to dementia (Goedert and Spillantini, 2006). The lack of established universal biomarker cutoffs makes the calculation of internal reference values mandatory for each laboratory both for clinical and research purposes This calculation is often critically influenced by the choice and composition of AD and control groups; the clinically defined AD group may include patients affected by other forms of dementia (e.g., FTD and DLB) due to misdiagnosis, while the control group is often very heterogeneous due to the inclusion of subjects diagnosed with other neurological diseases (OND) who underwent lumbar puncture (LP) for diagnostic purposes. The absence of standardized methodological and statistical approaches represents one of the most critical issues to study the distribution of CSF core AD biomarkers in different subgroups of patients and to validate in larger cohorts the cut-off values able to discriminate between AD and other
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have